Very High Oral Doses of Valacyclovir Significantly Inhibit HSV-1 DNA Shedding into Tears and Saliva of Herpes Simplex Virus Type-1 Latent Rabbits
James M. Hill(University of Oxford), Hilary W. Thompson(Center for Neurosciences), Timothy P. Foster(University of Florida Health), Vaibhav Tiwari(University of North Carolina at Chapel Hill), Christian Clément(Ophthalmology Associates (United States)), Partha S. Bhattacharjee(National Oceanic and Atmospheric Administration), Jeffery A. Hobden(Bipar), Harris E. McFerrin(Xavier University of Louisiana)
Investigative Ophthalmology & Visual Science
April 22, 2011
Cited by 0
Related Papers
Current and Emerging Developments in Subseasonal to Decadal Prediction
|Bulletin of the American Meteorological Society|2020|311
Current state of the global operational aerosol multi‐model ensemble: An update from the International Cooperative for Aerosol Prediction (ICAP)
|Quarterly Journal of the Royal Meteorological Society|2019|153
Ocular HSV-1 Latency, Reactivation and Recurrent Disease
|Seminars in Ophthalmology|2008|142
Using a 3-<i>O</i>-Sulfated Heparin Octasaccharide To Inhibit the Entry of Herpes Simplex Virus Type 1
|Biochemistry|2008|126
Ocular Herpes Simplex Virus: How are Latency, Reactivation, Recurrent Disease and Therapy Interrelated?
|Future Microbiology|2011|116